MASS X PRO formulation

LGD 4033 is a SARM that is more commonly known by the name Ligandrol but has also been called VK5211 or Anabolicum. In various animal studies, LGD 4033 has been shown to increase anabolic activity in the muscles and have positive effects on bone density in male rats experiencing hypogonadism, and have success treating female postmenopausal rats experiencing osteoporosis.

Additionally, various studies presented at the 62nd Annual Meeting of the Gerontology Society of America, found that use with LGD 4033 in animals increased resistance to fracture and bone mineral density after 12 weeks. This increase was noted in cancellous bone after a dose of 0.3 mg/kg per day and noted in cortical bone after a dose of 0.03 mg/kg per day (https://www.sec.gov/Archives/edgar/data/886163/000119312509239917/d425.htm). Furthermore, in both hypogonadal rats and normal rats LGD 4033 use was seen to increase skeletal muscle mass and muscle fiber diameter correlating to contractile power of the muscle which indicates greater muscle strength. In a fascinating study conducted by Roch et. Al, 3-month-old Sprauge-Dawley rats were ovariectomized and given LGD 4033 for 5 weeks. Each rat in the experimental groups was given doses of either 0.04, 0.4 or 4 mg/kg of body weight/day. After use, the researchers conducted an analysis of fiber size, capillary density, and various enzyme levels, additionally, the uterus, gastrocnemius, and soleus muscles were all weighed to document any changes before and after use (https://www.frontiersin.org/articles/10.3389/fendo.2020.556581/full#B30). When determining the effects of the LGD 4033 on the rats, researchers took samples from the quadriceps femoris muscle in order to determine changes in intramuscular fat content. In addition to determining changes in the intramuscular fat content, it was found that with treatment with LGD 4033 there was higher capillary density. Furthermore, with LGD 4033, there was higher activity of the enzyme citrate synthase in the gastrocnemius muscle. It was also found that after testing, the activity of the enzyme lactate dehydrogenase was higher in the longissimus muscle (https://www.frontiersin.org/articles/10.3389/fendo.2020.556581/full#B30). Overall, animal research with LGD 4033 had a uterotrophic effect when subjects were given a 4 mg dosage, beneficial effects on muscle vascularization as well as muscle metabolism were also found following use. Additionally, after the 4 mg dosage of LGD 4033, researchers reported increased muscular weight and increased weight of intramuscular fat content.

MK-677 is a long-acting, ghrelin receptor agonist and Human Growth Hormone stimulator, spiroindoline sulfonamide. It is also known as Ibutamoren, MK-677, L-163, 191, and formerly known as Oratrope. In a study performed by Jacks et. Al published in Endocrinology in 199g, 8 beagles were given MK-677 at doses of 0.25mg/kg, and it was found that Growth Hormone (GH) levels increased 5.3 times over baseline. At the 0.5mg/kg dose, GH levels increased 9 times over baseline GH rates, and at the 1mg/kg dose range, the GH levels increased by nearly 16 times that of baseline (15.8). It’s important to note that these doses were oral vs. intravenous or intramuscular injection. Insulin-like growth factor remained elevated by 30% after 8 hours, indicating MK-677 is a long-acting compound in beagles. GH was also elevated up to 6 hours. Study authors mentioned that cortisol was also elevated, however, it was modest compared to those in GH. But MK-677 is not just a GH secretagogue, it is also an orally active gherkin receptor agonist, meaning it will work on the ghrelin receptors. As explained by Zhang et al, “The ‘hunger hormone’ ghrelin activates the ghrelin receptor GHSR to stimulate food intake and growth hormone secretion and regulate reward signaling.” In addition to its role in hunger signaling, it also modulates stress, glucose, body weight, cognition, gut motility, the desire for food, adiposity, and even pain. An extensive study of MK-677’s chemical makeup in relation to ghrelin itself by Zhang’s research group discovered that MK-677 (termed Ibutamoren by their study), “mimics the first four N-terminal residues of ghrelin including the octanoyl moiety to bind at the bottom region of the ligand-binding pocket.” Study. If interested in the many target organs of ghrelin, see the following image at the link: Study. An interesting impact of MK-0677 on the ghrelin agonist that stimulates the GHS-R1a receptor has been shown to increase neural activity and decrease the death of neurons and neuroinflammation. In a study published in the International Journal of Molecular Sciences, researchers Jeong et. al, gave MK-677 to mice who were genetically predisposed to overexpress amyloid beta-peptide or Aβ, a protein responsible for the plaques and tangles shown in Alzheimer’s diseased brains. These mice were given MK-0677 via injection, at dose levels of 0.1, 1, and 3mg/kg for ten days. The second two groups had increased food intake through the ten-day study period, especially at the 3mg/kg dosing level. However, at the end of the ten days, body weight did not significantly differ between all dosing groups. Examination of the brains of the treated groups showed decreased Aβ deposition and decreased neuronal, synaptic losses as well as glial changes in the deep cortical layers of the brain. Researchers concluded that MK-677 also reduced the neuroinflammation and neurodegeneration associated with Aβ. Study.

RAD 140 SARM, or (2-chloro-4-[[(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl]amino]-3-methylbenzonitrile, also known as testolone was originally synthesized for Radius Health Inc. in conjunction with researchers from the University of Illinois, Obiter Research, and Cambridge Major Laboratories. Per the initial paper detailing the synthesis and preliminary findings of the compound, RAD140 has the stability to (t1/2 >2 h) in incubations with rat and monkey microsomes, as well as a high affinity for the androgen receptor (Ki = 7 nM), approximately 4 times the affinity than that of testosterone itself. At the same time, the nearest hormone receptor activated by RAD140 was progesterone at a level of 750nM. The earliest primate studies on RAD-140 indicated that even at the lowest dose range 0.1mg/kg, juvenile macaques gained a mean of ten percent in body weight, during the 28-day trial period, which was primarily confirmed to be lean body mass via DEXA scans performed before and after the trial period, however, this was somewhat variable.

In a study conducted by Jayaraman et. Al, gonadectomized, male rats were studied to see the effects supplementation with RAD 140 had in regards to neuroprotection in order to make conclusions regarding the usefulness of SARMs against neurodegenerative disorders. The rats were orally provided with 1 mg/kg a day of RAD 140 for 2 weeks. It was found that RAD140 was able to reduce apoptosis caused by Aᵝ, apoptosis activator II, and hydrogen peroxide by a significant amount. This is due to the role MAPK signaling plays in neuroprotection. Aᵝ was by far the most potent of the apoptosis insults introduced to the rats. After 24 hours of exposure to Aᵝ, 50% of viable neurons in the rats had decreased, however, when given RAD 140 in a concentration-dependent matter, the viability of the neurons had increased exponentially. The most effective concentration of RAD 140 was 100 nM, which led to approximately 90% neuron survival after Aᵝ exposure Study. In addition to measuring the neuroprotection against various apoptosis insults, researchers also measured the effects RAD 140 had on kainate-induced neuron death. It was found that when compared to treatment with a vehicle, kainate-induced neuron death was significantly reduced Study.

S23 is an orally available selective androgen receptor modulator or SARM. Originally developed by GTX as a form of hormonal male contraception in rats,it exhibits a high affinity for the androgen receptor with a Ki of 1.7 nM. Researchers, Jones et. Al published a research study comparing the effectiveness of S-23 in both castrated and intact male rats.

In castrated male rats, the effective dose of S23 in the prostate was 0.43 mg/d and 0.079 mg/d in the levator ani muscle. In intact male rats, doses greater than 0.1 mg/d of S-23 suppressed levels of luteinizing hormone (LH) by more than 50%. Furthermore, this dose of S-23 corresponded with decreased size of the prostate and increased size of the levator ani muscle Study. In intact males treated with S-23 as well as estradiol benzoate (to maintain sexual behavior), after 10 weeks there was no sperm found in the testis in four out of the six subjects and no reported pregnancies in all six of the subjects. After the treatment, infertility was completely reversed and 100% of the mating trials resulted in pregnancy.

The effects of S23 on muscle mass and body fat are comparable to the effects of anabolic steroids. In a study conducted in male rats it was discovered that while being treated with S23, the overall body weight and fat mass of the rats decreased. As it was previously mentioned, rats being treated with S23 were also given estradiol benzoate (EB) to maintain sexual behavior. EB is considered an estrogen which is known to cause muscle loss, however, when combined with S23 the effects of the estrogen were canceled out and the muscle mass of the male rats increased Study. . Additionally, in another study using rats, the effectiveness of S23 was tested against muscle loss due to long-term usage of glucocorticoids. This study also looked into the effects of S23 on castration-induced atrophy. In both cases, there was muscle loss but by supplementing S23 and testosterone to the rats the dexamethasone-induced dephosphorylation of Akt is blocked. Overall this study indicated that using S23 may be a more effective way of treating glucocorticoid-induced muscle loss Study.

MASS X PRO

Super concentrated formula

MASS X PRO formulation

possible side effects

Super concentrated formula

LGD4033

MK677

RAD140

S23

possible side effects